Aktienanalyse zu Intellia Therapeutics Inc (NTLA)NTLAIntellia Therapeutics Inc

Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Intellia Therapeutics is not a good buy right now due to significant financial losses and analyst concerns. The current price is $11.42, which is above Barclays' price target of $8, indicating a potential downside of 30%. Additionally, the RSI is at 36.2, suggesting the stock is oversold but lacks momentum for a recovery. The company is facing regulatory challenges and insider selling has increased by 2235.78%, raising red flags about future performance.

6 analysts cover NTLA: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 16.50.